Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

Prince Harry is on the campaign trail! On Tuesday, Jan. 28, the Duke of Sussex, 40, appeared in a video to encourage people ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

London stocks were set to fall at the open on Monday following a mostly weaker Asian session. The FTSE 100 was called to open ...

In an exclusive poll for City AM, Joanna Hodgson surveys major firms to see if hybrid working is still king in the UK ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

The Chalk River Nuclear Facility is cited as the largest supplier of medical radioisotopes in the world. (Chalk River was ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.